Lee Johnson Capital Management LLC Takes $6.55 Million Position in Danaher Corporation $DHR

Posted by Geri Gentry on Aug 18th, 2026

Lee Johnson Capital Management LLC acquired a new position in shares of Danaher Corporation (NYSE:DHR – Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 9,091 shares of the conglomerate’s stock, valued at approximately $6,546,000. Danaher comprises about 2.0% of Lee Johnson Capital Management LLC’s portfolio, making the stock its 13th largest holding.

A number of other institutional investors have also added to or reduced their stakes in the company. Grandfield & Dodd LLC purchased a new stake in Danaher during the second quarter valued at about $2,404,000. Argyle Capital Partners LLC bought a new position in shares of Danaher during the 2nd quarter valued at about $1,137,000. B & T Capital Management DBA Alpha Capital Management purchased a new position in shares of Danaher during the 2nd quarter valued at about $10,860,000. MidFirst Bank bought a new stake in Danaher in the 2nd quarter worth approximately $46,000. Finally, BlackRock Inc. purchased a new stake in Danaher in the second quarter worth approximately $9,404,633,000. Institutional investors own 79.05% of the company’s stock.

Danaher Trading Down 0.0%

Shares of DHR opened at $202.44 on Tuesday. The stock has a market capitalization of $142.31 billion, a P/E ratio of 35.96, a PEG ratio of 2.52 and a beta of 0.78. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The firm has a fifty day simple moving average of $193.52 and a two-hundred day simple moving average of $192.67. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80.

Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. The firm had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.77 earnings per share. On average, research analysts anticipate that Danaher Corporation will post 8.53 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Jefferies Financial Group restated a “buy” rating and issued a $245.00 price objective on shares of Danaher in a report on Tuesday, April 21st. JPMorgan Chase & Co. decreased their target price on shares of Danaher from $275.00 to $245.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 22nd. Wall Street Zen downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. UBS Group cut their price target on shares of Danaher from $270.00 to $250.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. Finally, DZ Bank started coverage on Danaher in a report on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average target price of $228.91.

View Our Latest Stock Report on Danaher

About Danaher

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.